Table 6.
Placebo | Regadenoson | P valuea | |||
---|---|---|---|---|---|
n | Mean ± SD | n | Mean ± SD | ||
Asthma stratum | |||||
FEV1 (L) | |||||
Baseline | 176 | 2.41 ± 0.689 | 356 | 2.35 ± 0.623 | |
Change at Hour 2 | 174 | −0.05 ± 0.160 | 351 | −0.01 ± 0.129 | .0029** |
FVC (L) | |||||
Baseline | 176 | 3.22 ± 0.883 | 356 | 3.16 ± 0.829 | |
Change at Hour 2 | 174 | −0.06 ± 0.208 | 351 | −0.03 ± 0.168 | .0789 |
FEV1/FVC ratio | |||||
Baseline | 176 | 74.88 ± 7.510 | 356 | 74.59 ± 7.084 | |
Change at Hour 2 | 174 | 0.16 ± 3.329 | 351 | 0.52 ± 2.562 | .2087 |
COPD stratum | |||||
FEV1 (L) | |||||
Baseline | 151 | 1.70 ± 0.630 | 316 | 1.70 ± 0.655 | |
Change at Hour 2 | 147 | −0.01 ± 0.152 | 313 | −0.00 ± 0.159 | .6189 |
FVC (L) | |||||
Baseline | 151 | 2.75 ± 0.833 | 316 | 2.83 ± 0.899 | |
Change at Hour 2 | 147 | −0.04 ± 0.230 | 313 | 0.00 ± 0.239 | .0258* |
FEV1/FVC ratio | |||||
Baseline | 151 | 61.95 ± 12.684 | 316 | 60.00 ± 13.191 | |
Change at Hour 2 | 147 | 0.31 ± 3.177 | 313 | −0.30 ± 3.571 | .0289* |
COPD, Chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV 1, forced expiratory volume in 1 second; SD, standard deviation.
*,**Statistical significance at level of P = .05 and P = .01, respectively.
a F test from ANCOVA with treatment and investigator site as main effects and baseline value as a covariate in the model.